Ipsen Halts Phase II FALKON Trial in Ultra-Rare FOP
Paris, France, December 19, 2025 — Ipsen, a global biopharmaceutical company, announced an update on its pivotal Phase II...
Phase II trial
Advertisement
Tiakis Advances Tiprelestat into Phase II for Pulmonary Hypertension
Kiel, Germany, December 2, 2025 — Tiakis Biotech has announced that it has successfully completed the required preclinical data...
CardiolRx Phase II Trial Shows Structural Heart Recovery in Myocarditis
Toronto, December 1, 2025 — New clinical data from the Phase II ARCHER trial reveal that CardiolRx™, Cardiol Therapeutics’...
FluoGuide’s Q3 2025 Report Underscores Regulatory Momentum and Clinical Progress
KØBENHAVN, DK — November 27, 2025. FluoGuide A/S has released its Q3 2025 interim report, outlining a quarter marked...
Arch Biopartners Expands Phase II Kidney Injury Trial in Canada
TORONTO, November 5, 2025 — Arch Biopartners Inc. (TSXV: ARCH, OTCQB: ACHFF) announced that the Fraser Health Research Ethics...
Advertisement
